|
|
 |
|
Viewing report
|
|
|
|
CNS Drug Discoveries: What the Future Holds 2008
Espicom Business Intelligence Ltd, Aug 2008, Pages: 446
A comprehensive examination of 5 CNS therapy areas: multiple sclerosis, Parkinson's disease, Alzheimer's disease, schizophrenia and depression. The report includes unique market share and sales forecasts by product to 2014, as well as detailed competitor analysis of current and upcoming products.
With this new 4000+ page analysis you can:
- Easily evaluate and understand the prospects for 60 leading and upcoming products
- Assess the impact on companies of new product introduction
- Understand the impact of generic competition in key sectors
- Appreciate the drivers and dampeners which will help or hinder market growth
- Review the Phase II product pipeline
For each therapy area the report provides:
- Comprehensive Overview
- Patient statistics:
- Prevalence, diagnosed and treatment rates
- Patient populations in the US, Europe and Japan
Growth drivers:
- Risk factors (genetics, age, sex), medical guidelines, unmet clinical need and off-label use in other CNS disorders
Growth dampeners:
- Safety issues, label changes, impact of generics, reimbursement and ethical issues
An overview of the value of the CNS market:
- Global sales
- Sales growth to 2014
- Major players and market share 2007 and 2014
- Current treatments
- Competitor analysis of leading brands and companies
- Patent exposure
- Sales forecasts by product 2007-2014
Drugs in Phase II/III development:
- Focus on new classes of drugs and companies involved
- Sales forecasts by year of product launch to 2014
Unique competitor ratio analysis:
- Drugs within each sector are analysed in the report using 5 point criteria for success evaluation
Who will be the winners & losers?
- Identify the winners and losers within each sector based on competitor analysis, current pipeline products and market conditions
Understand the prospects for this US$92 billion market! The global market for CNS disorders is now one of the largest therapeutic sectors with sales estimated at almost US$92 billion in 2007.
Also available
CNS Drug Discoveries: Alzheimers Disease Chapter
CNS Drug Discoveries: Depression Chapter
CNS Drug Discoveries: Multiple Sclerosis Chapter
CNS Drug Discoveries: Parkinsons Disease Chapter
CNS Drug Discoveries: Schizophrenia Chapter
Customers who bought this item also bought
The CNS Market Outlook to 2013: Competitive Landscape, Pipeline Analysis and Growth Opportunities
The CNS Market Outlook to 2012
Pipeline Insight: Orphan Diseases in CNS - Part II: Amyotrophic Lateral Sclerosis
CNS Therapeutics - A World Market Review
CNS Therapeutics - A World Market Review
Pipeline Insight: Orphan Diseases in CNS - Part I: Huntingtons Disease
CNS Therapeutics - Global Strategic Business Report
The Asian Cardiovascular Market Outlook to 2014: Regional and Therapeutic Analysis, Pipeline Impact and Growth Opportunities
Biosimilars (2009 - 2014)
The CNS Market 2008 Report
CNS Drug Discoveries: Neurodegenerative Disorders Chapter
CNS Biomarkers: Players, Products and Prospects (Volume II)
|
|
|
|
